EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Predictive Value of Neutrophil‐To‐Lymphocyte Ratio ( NLR ) for Response to Neoadjuvant Immunochemotherapy in Resectable IIA – IIIB Non‐Small Cell Lung Cancer in Real‐World Practice

Di Meng, Jiacong Liu, Gaoqi Ye, Linhai Zhu, Xuhua Huang, Xiayi Lv, Jian Hu iD

Thoracic Cancer · 2026-07 · 17 (13)

DOI: 10.1111/1759-7714.70315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 02.07.2026. Verfasst von Di Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Neutrophils, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Projects of "Vanguard" and "Leading Goose", the National Key Research and Development Program of China, Research Center for Lung Tumor Diagnosis and Treatment of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A significant clinical challenge remains the identification of non‐small cell lung cancer (NSCLC) patients who will derive maximum benefit from neoadjuvant immunochemotherapy. The neutrophil‐to‐lymphocyte ratio (NLR) may offer critical insights into the host's capacity to mount an effective anti‐tumor response.

Methods

This retrospective study consecutively included patients with stage IIA–IIIB NSCLC who received 2–4 cycles of platinum‐based immunochemotherapy prior to planned resection at the Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine from 2017 to 2022.

Results

A total of 317 patients were included in our study and divided into two groups according to the median baseline NLR (3.27) of the whole population: low NLR (< 3.27) group (160 patients) and high NLR (≥ 3.27) group (157 patients). The rate of MPR in the low NLR group was significantly higher than that in the high NLR group (58.3% vs. 38.5%, p = 0.008). The median PFS in the low NLR group was not reached and 21.6 months (95% confidence interval [CI], 16.9 to 26.3) in the high NLR group (hazard ratio [HR] for disease progression, disease recurrence, or death, 0.431; 95% CI, 0.312 to 0.594; p < 0.001). The median OS in the low NLR group was not reached and 33.2 months (95% CI, 18.8 to 47.6) in the high NLR group (HR for death, 0.416; 95% CI, 0.295 to 0.586; p < 0.001).

Conclusions

A low pre‐treatment NLR is a predictive marker of enhanced pathological response and improved survival outcomes in IIA–IIIB NSCLC patients undergoing neoadjuvant immunochemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeutrophilsCarcinoma, Non-Small-Cell LungLung NeoplasmsLymphocytesNeoadjuvant TherapyImmunotherapyHumansFemaleMaleRetrospective StudiesMiddle AgedAgedPrognosisNeoplasm Staging

Stichwörter der Autor:innen

neoadjuvant immunochemotherapyneutrophil‐to‐lymphocyte ratio (NLR)non‐small‐cell lung cancer (NSCLC)predictive valuereal‐world practice

Autor:innen und Institutionen

  • Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Key Laboratory of Clinical Evaluation Technology for Medical Device of Zhejiang Province, Hangzhou, China.

ORCID-Profile: Jian Hu

Förderung

  • Key Research and Development Projects of "Vanguard" and "Leading Goose"
  • the National Key Research and Development Program of China
  • Research Center for Lung Tumor Diagnosis and Treatment of Zhejiang Province

Zitieren

APA

Meng, D., Liu, J., Ye, G., Zhu, L., Huang, X., Lv, X., & Hu, J. (2026). The Predictive Value of Neutrophil‐To‐Lymphocyte Ratio ( NLR ) for Response to Neoadjuvant Immunochemotherapy in Resectable IIA – IIIB Non‐Small Cell Lung Cancer in Real‐World Practice. Thoracic Cancer, 17(13). https://doi.org/10.1111/1759-7714.70315

Vancouver

Meng D, Liu J, Ye G, Zhu L, Huang X, Lv X, et al. The Predictive Value of Neutrophil‐To‐Lymphocyte Ratio ( NLR ) for Response to Neoadjuvant Immunochemotherapy in Resectable IIA – IIIB Non‐Small Cell Lung Cancer in Real‐World Practice. Thoracic Cancer. 2026;17(13). doi:10.1111/1759-7714.70315

BibTeX
@article{Meng2026,
  author = {Meng, Di and Liu, Jiacong and Ye, Gaoqi and Zhu, Linhai and Huang, Xuhua and Lv, Xiayi and Hu, Jian},
  title = {The Predictive Value of Neutrophil‐To‐Lymphocyte Ratio ( NLR ) for Response to Neoadjuvant Immunochemotherapy in Resectable IIA – IIIB Non‐Small Cell Lung Cancer in Real‐World Practice},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {13},
  doi = {10.1111/1759-7714.70315}
}
Kostenlos starten →